Figure S1


FJMUUH
(n=870)
380
Tissue microarray
(Jan 2013 to Apr 2014)
265
were randomised
(Jan 2012 to Oct 2015)
165 receiving
neoadjuvant therapy
(Mar 2019 to Nov 2021)
60 for RNA-Seq
& Whole-Exon-Seq
(May 2020 to May 2021)
19 excluded due
to incomplete data
12 excluded due
to incomplete data
68 excluded
due to lack of tissue
samples or limited
tumor area
361
Tissue microarray
FJMUUH1 Cohort
253
FFPE section
FJMUUH2 Cohort
48 GC receiving
neoadjuvant
ICI therapy plus
chemotherapy
(nICI cohort)
49 GC receiving
neoadjuvant
chemotherapy
(nCT cohort)
KMUFAH
(n=106)
GMUATH
(n=60)
BMCFAH
(n=100)
LCH
(n=98)
Validation
South China cohort
(n=166)
Central China cohort
(n=100)
North China cohort
(n=98)